The novel fusogenic peptides improve the delivery of therapeutics for ovarian cancer through their ability to enhance endosomal escape and delivery of bioactive therapeutics. Epithelial ovarian cancer is the 5th leading cancer among women, with a 49% five-year survival rate. Current treatment strategies for ovarian cancer include surgical removal, chemotherapy, and radiation; however, these treatments often prove ineffective or toxic…
Inventor: Angela Alexander-Bryant, Timothy Samec
This patient risk-assessment machine learning algorithm predicts patient response to cardiac resynchronization therapy (CRT) intervention enabling more informed selection criteria and improved rates of therapy success. Approximately 90,000 patients receive cardiac resynchronization therapy per year, with only 50% of that population benefitting. This directly results from the uncertainties surrounding which patients will actually benefit from the procedure. Providing insights into…
Inventor: Will Richardson, Anamul Haque, William Douglas Stubbs Jr.
Clemson University researchers have developed an in vitro
myocardial therapy screening platform possessing superior
physiological relevance that enables clinically translatable metrics
for therapy efficacy and cardiotoxicity evaluation.
Inventor: William Richardson, Samuel Coeyman, Jonathan G. Heywood
Clemson University researchers have developed a biomaterial that mimics the structure and function of human NP to mitigate or halt progression of IDD.
Inventor: Jeremy Mercuri, Christopher Fernandez
Clemson University researchers have developed an anti-biofouling approach that can inactivate bacteria without introducing chemicals into the feed water and without pausing operation of the membrane treatment process.
Inventor: Ezra Cates